IDH2 and central nervous system cancer: Phase I/II trials of enasidenib for other tumor types, such as IDH2‐mutated MDS, glioma, or angioimmunoblastic T‐cell lymphoma with an IDH2 mutation, and advanced hematologic malignancies with an IDH2 mutation, are under evaluation (NCT03744390, NCT02273739, and NCT01915498).